PHAT Phathom Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PHAT

Price (delayed)

$9.89

Market cap

$578.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.93

Enterprise value

$632.93M

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, ...

Highlights
The quick ratio has surged by 68% year-on-year and by 10% since the previous quarter
The equity rose by 2.7% YoY
The EPS is up by 22% year-on-year but it has declined by 2.9% since the previous quarter
PHAT's debt has surged by 112% year-on-year and by 96% since the previous quarter
PHAT's net income is down by 14% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.phathompharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of PHAT
Market
Shares outstanding
58.48M
Market cap
$578.34M
Enterprise value
$632.93M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
743.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
928.05
Earnings
Revenue
$682,000
EBIT
-$159.62M
EBITDA
-$159.05M
Free cash flow
-$139.21M
Per share
EPS
-$3.93
Free cash flow per share
-$2.71
Book value per share
-$1.27
Revenue per share
$0.01
TBVPS
$8.07
Balance sheet
Total assets
$413.84M
Total liabilities
$486.6M
Debt
$438.85M
Equity
-$72.76M
Working capital
$358.65M
Liquidity
Debt to equity
-6.03
Current ratio
10.25
Quick ratio
9.95
Net debt/EBITDA
-0.34
Margins
EBITDA margin
-23,321%
Gross margin
75.5%
Net margin
-29,558.9%
Operating margin
-24,532.6%
Efficiency
Return on assets
-76.1%
Return on equity
N/A
Return on invested capital
-59.3%
Return on capital employed
-42.6%
Return on sales
-23,405.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PHAT stock price

How has the Phathom Pharmaceuticals stock price performed over time
Intraday
1.33%
1 week
7.73%
1 month
0.3%
1 year
-14.89%
YTD
8.32%
QTD
-6.87%

Financial performance

How have Phathom Pharmaceuticals's revenue and profit performed over time
Revenue
$682,000
Gross profit
$515,000
Operating income
-$167.31M
Net income
-$201.59M
Gross margin
75.5%
Net margin
-29,558.9%
The company's operating income fell by 16% QoQ but it rose by 3% YoY
PHAT's net income is down by 14% since the previous quarter

Growth

What is Phathom Pharmaceuticals's growth rate over time

Valuation

What is Phathom Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
743.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
928.05
The EPS is up by 22% year-on-year but it has declined by 2.9% since the previous quarter
The equity rose by 2.7% YoY

Efficiency

How efficient is Phathom Pharmaceuticals business performance
The ROIC has grown by 44% YoY and by 11% from the previous quarter
Phathom Pharmaceuticals's ROA has increased by 30% YoY and by 13% from the previous quarter

Dividends

What is PHAT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PHAT.

Financial health

How did Phathom Pharmaceuticals financials performed over time
The total assets is 15% smaller than the total liabilities
The total assets has surged by 151% year-on-year and by 75% since the previous quarter
The total liabilities has soared by 103% year-on-year and by 91% since the previous quarter
The debt to equity has dropped by 118% year-on-year but it has surged by 52% since the previous quarter
PHAT's debt has surged by 112% year-on-year and by 96% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.